# VC004

Source: https://onco.cc/drugs/vc004/  
OnCo record `vc004` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VC004 is an experimental small-molecule drug from Jiangsu vcare pharmaceutical technology co. in phase 3 trials, with its target not yet stated publicly.

## Summary

VC004 is a small-molecule drug developed by Jiangsu vcare pharmaceutical technology co.. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06658353 (Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumours). The largest, NCT06658353, plans to enrol 54 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of VC004: https://clinicaltrials.gov/search?intr=VC004

## Connected records

- trials: [Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors](https://onco.cc/trials/nct06658353/)

---
JSON: https://onco.cc/api/v1/entities/vc004.json